Perfil
David I.
Stirling has a career history that includes founding positions at two companies.
He founded Celgene SAS in 1986 and BioTheryX, Inc. in 2007.
At BioTheryX, Inc., he currently holds the title of Director.
Cargos activos de David I. Stirling
Empresas | Cargo | Inicio |
---|---|---|
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Founder | 01/01/2007 |
Antiguos cargos conocidos de David I. Stirling.
Empresas | Cargo | Fin |
---|---|---|
Celgene SAS
Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Founder | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
Celgene SAS
Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Health Technology |
- Bolsa de valores
- Insiders
- David I. Stirling